April 2, 2025—Werfen announced the commercialization of its ACL Top Family 70 series hemostasis testing systems in North America, following FDA 510(k) clearance and Health Canada licensure.
The systems feature a two-step automated performance verification process and automated preanalytical checks, which detect and flag samples that exceed assay-specific thresholds for hemoglobin, icterus, and lipemia, as well as underfilled samples and those with clots. With HemoHub Intelligent Data Manager, synergistic integration allows uniform application of a laboratory’s quality management system across multiple instruments and sites from a centralized location. To ensure security and uninterrupted functionality, cybersecurity and privacy by design are integrated.
The five models accommodate a range of testing needs, from low- to medium-volume labs (ACL Top 370), medium- to high-volume labs (ACL Top 570), and highest-volume, fully automated labs (ACL Top 770, ACL Top 770 S, ACL Top 770 LAS). All offer the same quality results, intuitive software, reagent portfolio, features, usability, and training.